Perspectives in Melanoma XIV
September 17-18, 2010
Amsterdam, The Netherlands
The Novotel Amsterdam City
Friday, 17 September, 2010
9:00
Welcome address
9:05
Audience response system outcomes evaluation
Session I: Updates in epidemiology, genetics, and basic research
Moderators: Jan Willem Coebergh, MD, PhD and Alan Spatz, MD
9:15
UVA versus UVB – the Iceland story revisited
Philippe Autier, MD, MPH
9:35
New molecular classification system proposals
Alan Spatz, MD
9:55
Melanoma stem cells
Lionel Larue, PhD, HDR
10:15
Angiotropism and extravascular migratory metastasis in melanoma
Raymond L. Barnhill, MD
10:35
Break
Session II: Updates in diagnostics and surgery
Moderators: Alessandro Testori, MD and
John B.A.G. Haanen, MD, PhD
11:00
Confocal microscopy for diagnosis in the clinic
Giovanni Pellacani, MD
11:20
New developments with ultrasound for staging of primary melanoma
Christiane A. Voit, MD, PhD
11:40
Electrochemotherapy from superficial to visceral metastases
Alessandro Testori, MD
12:00
Complete lymph node dissection: mandatory or an option for whom?
Alexander C.J. van Akkooi, MD
12:20
Panel discussion
12:30
Lunch
Session III: Systemic therapies:
Novel small molecule inhibitors and resistance
Moderators: John M. Kirkwood, MD and Poulam M.Patel, PhD, FRCP
14:00
Importance of pathways: How do they relate to resistance patterns?
Richard Marais, PhD
14:25
Resistance patterns and new combinations
Keith T. Flaherty, MD
14:50
Overview of non-PLX inhibitors
Reinhard Dummer, MD
15:15
Panel discussion
15:30
Break
Session IV: Oral abstract presentations
16:00
Presentation of selected abstracts
17:45
Audience response outcomes evaluation
18:00
Adjourn
18:30
Evening satellite symposium
Identifying High Risk Patients for Adjuvant Treatment
Presented by MSD Oncology
Saturday, 18 September 2010
8:30
Introduction to day two
8:35
Audience response system outcomes evaluation
Session V: Immunomodulators, vaccinations, and resistance
Moderators: Alexander M.M. Eggermont, MD, PhD and Caroline Robert, MD
8:45
anti-CTL-A4
Steven J. O’Day, MD
9:05
Immunity to NY-ESO-1: Overcoming the mechanisms of melanoma-induced immunosuppression
Hassane M. Zarour, MD
9:25
Immuno-oncology: Creating the framework for a new era of cancer therapy
Axel Hoos, MD, PhD
9:50
Dissecting therapy-induced T-cell responses in melanoma
Ton N. Schumacher, PhD
10:10
Panel discussion
10:20
Break
Session VI: Oral abstract presentations
Moderators: Dirk Schadendorf, MD and John B.A.G. Haanen, MD, PhD
10:45
Presentation of selected abstracts
11:15
Special address to the melanoma community
Valerie Guild of the AIM at Melanoma Foundation
11:25
Lunch
Session VII: Clinical trial overview
Moderators: John M. Kirkwood, MD and
Alexander M.M. Eggermont, MD, PhD
12:25
CTEP melanoma update
Claudio Dansky Ullmann, MD
12:45
Ipilimumab in stage IV
Steven J. O’Day, MD
12:50
Ipilimumab in stage III
Alexander M.M. Eggermont, MD, PhD
12:55
Tremelimumab in stage IV
Caroline Robert, MD
13:05
Phase III BRAF and c-KIT trials
Keith T. Flaherty, MD
13:15
GM-CSF-encoding oncolytic herpes simplex virus
Alexander M.M. Eggermont, MD, Phd
13:25
Tasisulam
John M. Kirkwood, MD
13:35 Audience response outcome measurement
13:45 Closing comments
14:00 Adjourn
